2022 World Conference on Lung Cancer (ePosters)-EP03.01-011. Prevalence of KRASMutations in Treatment-naïve Non-small Cell Lung Cancer Patients in Hong Kong

EP03.01-011. Prevalence of KRASMutations in Treatment-naïve Non-small Cell Lung Cancer Patients in Hong Kong

Pdf Summary

This study aimed to examine the prevalence of KRAS and KRAS G12C mutations in treatment-naïve non-small cell lung cancer (NSCLC) patients in Hong Kong. The study was conducted at a single center and included 2,120 NSCLC patients who had not received any prior treatment. The molecular testing for KRAS mutations was performed using Sanger sequencing of formalin-fixed, paraffin-embedded tumor tissue samples collected from January 2012 to October 2021. Results showed that out of the 2,120 patients, 205 had KRAS mutations, indicating a prevalence of 9.67%. Among these KRAS-mutated patients, the overall prevalence of KRAS G12C mutation was found to be 4.67%, with 99 patients having this specific mutation. This study provides the first report on the prevalence of KRAS mutations in Hong Kong NSCLC patients from a single center. It also found similar prevalence rates of KRAS and KRAS G12C mutations compared to studies conducted in mainland China. The findings of this pilot study lay the groundwork for further investigation and estimation of potential NSCLC patients who can benefit from emerging KRAS medications. Understanding the prevalence of specific driver mutations like KRAS G12C is crucial for developing targeted therapies and improving patient outcomes.

Asset Subtitle

James C Ho

Meta Tag

Speaker James C Ho

Topic Epidemiology

Keywords

prevalence

KRAS mutations

KRAS G12C mutations

non-small cell lung cancer

NSCLC patients

Hong Kong

molecular testing

Sanger sequencing

tumor tissue samples

targeted therapies